ARTICLE | Finance
Precirix building out radiotherapy platform with €80M series B
The Belgian company is branching out into alpha emitters and growing its geographical footprint
March 18, 2022 8:16 PM UTC
With clinical studies of its lead iodine-based candidate under way, Precirix is deploying its series B to expand its pipeline into other radioisotopes, including alpha-emitters.
“We want to demonstrate that we have a platform on our hands, not just one product,” CEO Ruth Devenyns told BioCentury...
BCIQ Target Profiles
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)